2023
Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes
Shariq O, Abrantes V, Lu L, Tebben P, Foster T, Dy B, Lyden M, Young W, McKenzie T. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes. Surgery 2023, 175: 8-16. PMID: 37891063, DOI: 10.1016/j.surg.2023.05.044.Peer-Reviewed Original ResearchConceptsMedian disease-free survivalDisease-free survivalPrimary hyperparathyroidismSurgical approachTruncated exon 2Total parathyroidectomyPostoperative outcomesExon 2Aggressive pNETsShorter median disease-free survivalHigh risk of recurrenceLong-term postoperative outcomesIncidence of postoperative hypoparathyroidismMultiple endocrine neoplasia type 1Incidence of permanent hypoparathyroidismPancreatic neuroendocrine tumorsAnalyzed baseline characteristicsRisk of recurrenceYounger median ageGermline pathogenic variantsHypoparathyroidism rateMEN1 genotypeMEN1 variantsPermanent hypoparathyroidismNeuroendocrine tumors
2022
Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases
Szabo Yamashita T, Gudmundsdottir H, Foster T, Lyden M, Dy B, Tebben P, McKenzie T. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. The American Journal Of Surgery 2022, 225: 699-702. PMID: 36270819, DOI: 10.1016/j.amjsurg.2022.10.018.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismFamilial casesSingle-center retrospective reviewSporadic casesTime to recurrenceSingle gland diseaseRate of recurrenceLong-term outcomesApparent sporadic casesSporadic groupRetrospective reviewSurgical outcomesMEN-1Pediatric patientsGland diseaseFamilial syndromesSurgical pathologyFollow-upGenetic testingPatientsRecurrenceFamily cohortSyndromeMonthsOutcomes
2016
Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment
Tebben P, Singh R, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews 2016, 37: 521-547. PMID: 27588937, PMCID: PMC5045493, DOI: 10.1210/er.2016-1070.Peer-Reviewed Original ResearchConceptsVitamin D receptorD receptorVitamin D-mediated hypercalcemiaElevated serum calcium concentrationsAssociated with elevated serumProduction of 1,25-dihydroxyvitamin DSuppressing PTH concentrationsAssociated with malignancyReduced bone densityRenal stone formersSerum calcium concentrationVitamin D metabolitesVitamin D<sub>3</sub>Primary hyperparathyroidismElevated serumPTH concentrationsMonoallelic mutationsClinical featuresCYP24A1 geneD metabolitesGranulomatous diseaseBiochemical diagnosisTumor cellsVitamin DHypercalcemiaPrimary Hyperparathyroidism in Children and Adolescents
Lo H, Tebben P. Primary Hyperparathyroidism in Children and Adolescents. 2016, 117-128. DOI: 10.1007/978-3-319-25880-5_14.ChaptersPrimary hyperparathyroidismMultiple-gland diseaseSporadic primary hyperparathyroidismDegree of hypercalcemiaAssociated with greater morbidityEnd-organ damageTime of diagnosisHigh-volume surgeonsParathyroid hormone concentrationsTarget organ sensitivityPediatric patientsRare conditionYounger patientsGreater morbidityEndocrine surgeryEndocrine disordersFamilial diseaseAffected organsHormone concentrationsHyperparathyroidismSurgeryPatientsDiseaseAdultsHypercalciuria
2013
Pediatric Endocrine Surgery: A 20-Year Experience at the Mayo Clinic
Kundel A, Thompson G, Richards M, Qiu L, Cai Y, Schwenk F, Lteif A, Pittock S, Kumar S, Tebben P, Hay I, Grant C. Pediatric Endocrine Surgery: A 20-Year Experience at the Mayo Clinic. The Journal Of Clinical Endocrinology & Metabolism 2013, 99: 399-406. PMID: 24423286, DOI: 10.1210/jc.2013-2617.Peer-Reviewed Original ResearchConceptsNeck dissectionAdrenocortical carcinomaMayo ClinicCases of permanent hypoparathyroidismHigh-volume endocrine surgeonsSuccinate dehydrogenase subunit B mutationLateral neck dissectionCongenital adrenal hyperplasiaAge of patientsHigh-volume surgeonsSix-month follow-upMultiglandular diseaseRecurrent hyperparathyroidismAdrenal hyperplasiaPermanent hypoparathyroidismUnilateral adrenalectomyEndocrine proceduresPrimary hyperparathyroidismCushing's syndromeThyroid proceduresDistal pancreatectomyPancreatic proceduresParaganglioma patientsTertiary hyperparathyroidismComplication rate
2010
Severe Hypercalcemia due to Primary Hyperparathyroidism with MEN 2A
Thompson G, Dy B, Vazquez B, Tebben P, Kumar S. Severe Hypercalcemia due to Primary Hyperparathyroidism with MEN 2A. World Journal Of Endocrine Surgery 2010, 2: 131-133. DOI: 10.5005/jp-journals-10002-1037.Peer-Reviewed Original ResearchSevere hypercalcemia due to primary hyperparathyroidismHypercalcemia due to primary hyperparathyroidismPrimary hyperparathyroidismSevere hypercalcemiaParathyroid adenomaMEN 2ASurgical managementRare presentation of primary hyperparathyroidismCalcium levelsPresentation of primary hyperparathyroidismDecreased bone mineral densityElevation of serum calciumSingle parathyroid adenomaTreatment of hyperparathyroidismEarly surgical managementBone mineral densityTime of diagnosisParathyroid carcinomaRare presentationClinical presentationSerum calciumMineral densitySevere elevationClinical manifestationsDifferential diagnosis
2004
Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism
Tebben P, Singh R, Clarke B, Kumar R. Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism. Mayo Clinic Proceedings 2004, 79: 1508-1513. PMID: 15595334, DOI: 10.4065/79.12.1508.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersDihydroxycholecalciferolsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHumansHyperparathyroidismMaleMiddle AgedParathyroid GlandsParathyroid HormoneParathyroidectomyPostoperative CarePreoperative CareProbabilityProspective StudiesSampling StudiesSensitivity and SpecificitySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsBone-specific alkaline phosphataseBone-specific alkaline phosphatase concentrationsFibroblast growth factor 23Primary hyperparathyroidismParathyroid hormoneSerum phosphorus concentrationFGF23 concentrationsSerum calciumSurgically treated primary hyperparathyroidismElevated serum calciumLow-normal rangeParathyroid hormone concentrationsAdult patientsPreoperative stateSerum phosphorusPostoperative stateHyperparathyroidismHealthy controlsFibroblast growth factorPatientsFGF23Growth factorSurgerySerumPhosphorus homeostasis